NFKB1 and neoplasm: Although evidence indicates that TRAF2, by promoting the activation of NF-κB, enhances the CD8+-related anti-tumor immune response [127], hints to double-edged sword effects of TRAF2 hyperactivation are rare, indicating it as mostly pro-cancerogenic.